A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

March 30, 2030

Conditions

Wilson Disease

Interventions

BIOLOGICAL

intravenous LY-M003

The study was a single intravenous infusion of LY-M003 at a rate of 1 mL per minute.

Trial Locations (1)

RECRUITING

First Affiliated Hospital of Zhejiang University, Hangzhou

All Listed Sponsors

lead

Chaohui Yu

OTHER